Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small-cell lung cancer and interstitial lung disease
Not Applicable
Recruiting
- Conditions
- Patients with non-small-cell lung cancer and interstitial lung disease
- Registration Number
- JPRN-UMIN000050630
- Lead Sponsor
- Chiba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Disagree to study registration
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain carboplatin and paclitaxel/nab-paclitaxel rechallenge efficacy in NSCLC with ILD (JPRN-UMIN000050630)?
How does carboplatin-paclitaxel/nab-paclitaxel rechallenge compare to standard chemotherapy in NSCLC with interstitial lung disease?
Which biomarkers predict response to carboplatin and paclitaxel/nab-paclitaxel rechallenge in NSCLC with interstitial lung disease?
What are the pulmonary toxicity risks and management strategies for carboplatin-paclitaxel rechallenge in NSCLC with ILD?
How does nab-paclitaxel differ from paclitaxel in carboplatin rechallenge efficacy and safety for NSCLC with ILD?